This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.
Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of lung cancer drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.
This report (see brochure) provides a comprehensive review of lung cancer vaccines and reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers.
Today, more than 40 candidate lung cancer vaccines are in development or being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting approaches have been treated as single strategies. This report gives an overview of the status and clinical findings of these candidate vaccines, and gives developmental and market-related perspectives in this rapidly developing field.
- Late-stage (Phases 2/3, 3 and Approved, n = 5) pipeline vaccines and companies
- Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) pipeline vaccines and companies
- Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting lung cancer, Phase 1, 1/2 and 2
- Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and Approved
- Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic vaccines being evaluated for the treatment of lung cancer
- Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the treatment of lung cancer
- Commercial partnerships and collaborations on pipeline therapeutic vaccines
- Drug combination strategies in the evaluation of therapeutic vaccines for the targeting of lung cancer
- A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for the treatment of lung cancer
- Technical and market insights and perspectives in the development and clinical evaluation of therapeutic vaccines for the treatment of lung cancer
- Competitive and market-related information